The binding offer, announced in March, would see the maker of OneTouch brand and other blood glucose monitoring products change hands.
The deal is expected to close by year-end, New Brunswick-based J&J said in a news release, subject to customary approvals and conditions.
J&J said it will continue to serve the diabetes market through its medical device, pharmaceuticals and consumer businesses, including medications.
Read more from ROI-NJ:
- J&J announces $2.1B binding offer for its LifeScan unit
- Fortive offers $2.8B for J&J’s sterilization products unit